Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

OBJECTIVE: Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Michael J, Merton, Katherine W, Vijapurkar, Ujjwala, Balis, Dainius A, Desai, Mehul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291455/
https://www.ncbi.nlm.nih.gov/pubmed/28184166
http://dx.doi.org/10.2147/DMSO.S126291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291455/
https://www.ncbi.nlm.nih.gov/pubmed/28184166
http://dx.doi.org/10.2147/DMSO.S126291

Ejemplares similares